FDA approves new imaging drug for detecting spread of prostate cancer
https://www.facingourrisk.org/XRAY/new-imaging-for-prostate-cancer
Full article: https://www.fda.gov/news-events/press-announcements/fda-approves-first-psma-targeted-pet-imaging-drug-men-prostate-cancer
On December 1, 2020 the FDA approved a new type of imaging technology to confirm the spread of newly diagnosed prostate cancer that is suspected to be metastatic. The approval also includes use for confirming suspected recurrence in men who have rising PSA after treatment. The approval is based on two clinical trials that showed this new technique to be safe and consistent in accurately detecting cancer that has spread beyond the prostate gland. (1/7/21)
THIS INFORMATION HAS BEEN UPDATED on 5/10/2022: On March 23, 2022 the U.S. Food and Drug Administration (FDA) approved a new drug called Pluvicto to treat patients with metastatic castration-resistant prostate cancer. ON the same day, the FDA also approved a new imaging drug called Locametz (a brand of Gallium 68 PSMA-11) for identification of those patients who would benefit from treatment with Pluvicto. Read about the FDA approval of Pluvicto and Locametz here.
Este artículo está disponible en español.
Questions To Ask Your Health Care Provider
- What tests have already been done to detect spread of my prostate cancer?
- Is Ga 68 PMSA-11 an option for detecting spread of my prostate cancer? How often should I have it done?
- If Ga 68 PMSA-11 is not an option for me now, might it be an option in the future?
- What side effects might I experience with Ga 68 PMSA-11?
- Are any other agents or procedures available to detect the spread of my prostate cancer?
Open Clinical Trials
The following are studies looking at new methods for staging, monitoring and finding recurrence in people with prostate cancer.
- NCT02282137: 68Ga-PSMA PET-CT Scan for Diagnosis and Management of Prostate Cancer (PSMA). This study looks at the effectiveness of the 68Ga-PSMA-11 PET-CT scan to detect tumor location and measure size in patients with suspected or confirmed prostate cancer or prostate cancer that may have come back.
- NCT04030338: Prostate-Specific Membrane Antigen (PSMA) PET Scans to Find Prostate Cancer. This study will determine whether PET scans using PSMA are accurate and more effectively find prostate cancer than the standard methods.
- NCT04716725: 68Ga-PSMA-11 PET for the Diagnosis of Metastatic Castration Resistant Prostate Cancer. This trial assesses whether using 68Ga-PSMA-11 PET scans will help doctors learn more about the location of disease in the body.
- NCT04777071: An Investigational Scan (68Ga-PSMA-11 PET/CT) for the Imaging of Prostate Cancer. This trial studies how well 68Ga-PSMA-11 PET/CT scans work for imaging patients with prostate cancer.
- NCT04867603: Digital PET/CT Using [Ga-68]PSMA for Characterization of Prostate Lesions. This study evaluates a radioactive diagnostic drug called Gallium-68 Prostate Specific Membrane Antigen ([Ga-68]PSMA) to determine whether prostate abnormalities are cancer.
- NCT05160597: Image-Guided (68Ga-PSMA-11 PET/CT) Prostate Biopsy for the Diagnosis of Prostate Cancer in Men With Prior Negative/Inconclusive Biopsy. This study looks at how well an image-guided prostate biopsy using the imaging agent 68Ga-prostate-specific membrane antigen (PSMA)-11 with a PET/CT scan works in diagnosing prostate cancer in men with a prior negative or inconclusive prostate biopsy.
Several other clinical trials for monitoring patients with prostate cancer can be found here.
About FORCE
FORCE is a national nonprofit organization, established in 1999. Our mission is to improve the lives of individuals and families affected by adult hereditary cancers.